NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
Clinical Trials
32 trialsNCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT03114254 2022-11-18
JAVA-P
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT05471427 2022-07-22
ANCHISES
Azienda Ospedaliero-Universitaria Careggi
Completed
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT03101046 2022-02-10
TACTIK
UNICANCER
Phase 2 Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT02512458 2020-02-10
CABA-BONE
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01668459 2018-12-04
CabB1
University Hospital Birmingham NHS Foundation Trust
Phase 2/3 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT01649635 2016-07-06
PROSPECTA
Sanofi
Phase 4 Completed
NCT01541007 2015-11-02
ConCab
Karolinska University Hospital
Phase 2 Completed
NCT01600339 2015-05-12
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
Rambam Health Care Campus
Phase 2 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT01324583 2015-01-07
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sanofi
Phase 1 Completed
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed